Cetuximab and Panitumumab for Previously Untreated Metastatic Colorectal Cancer (TA439)

Technology Appraisal Guidance No. 439

Source: National Institute for Health and Care Excellence

This guidance replaces NICE technology appraisal guidance on cetuximab for the first-line treatment of metastatic colorectal cancer (TA176).

This guidance partially updates the terminated NICE technology appraisal on panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (TA240).

1. Guidance

1.1  Cetuximab is recommended, within its marketing authorisation, as an option for previously untreated epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in adults in combination with:

  • 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) or
  • 5-fluorouracil, folinic acid and irinotecan (FOLFIRI)

1.2 Panitumumab is recommended, within its marketing authorisation, as an option for previously untreated RAS wild-type metastatic colorectal cancer in adults in combination with:

  • FOLFOX or
  • FOLFIRI

1.3 The drugs are recommended only when the companies provide them with the discounts agreed in their patient access schemes.


A copy of the full document and background is available on the Internet at 

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:[email protected]

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer.
Issue Date: March 2017
Review Date: March 2020


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

Excessive steroid dosing highlighted in inflammatory bowel disease

Excessive steroid dosing highlighted in inflammatory bowel disease

Some patients with Crohn's disease or ulcerative colitis...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Femoston 1/10, Flixotide Nebules, Synalar C...

Blood Glucose Testing Strips and Meters

Blood Glucose Testing Strips and Meters

Compatible test strips for blood glucose meters.

intelog Learning's Espresso CPD helps GPs to top up credits for appraisal

intelog Learning's Espresso CPD helps GPs to top up credits for appraisal

Bite-size Espresso learning can help you top up your...